MaQxan 204™ is a clinically proven marigold extract delivering a precise 5:1 Lutein-to-Zeaxanthin ratio, engineered to help protect the macula from blue-light exposure associated with prolonged screen time and modern lifestyles.
MaQxan™ 204 is a premium, clinically proven marigold (Tagetes erecta) extract delivering a highly effective 5:1 ratio of Lutein to Zeaxanthin. It is manufactured by Ingex Botanicals (P) Limited, India, the manufacturing arm of Ingex Germany GmbH, and supplied to eye-health and nutraceutical brands across Europe.
Engineered to combat the optical stress of modern lifestyles, MaQxan™ 204 is the targeted solution for Computer Vision Syndrome (CVS) and Screen-related Macular Degeneration (SMD). High screen exposure depletes macular pigment, directly affecting visual quality, contrast sensitivity and sleep patterns. MaQxan™ 204 restores this critical protective layer.
Produced via a 100% natural, ethanol-only green-extraction process (hexane-free) with full seed-to-shelf traceability, and recognised with KFDA approval (Recognition No. 2025-70).
Everything you need to know about this clinically proven eye-health ingredient: origin, the 5:1 advantage, clinical proof, and certifications.
Derived from marigold (Tagetes erecta) via a completely backward-integrated supply chain, with high-xanthophyll seeds supplied to partner farmers across 5,000+ acres.
A clinically optimised 5:1 Lutein-to-Zeaxanthin ratio precisely tailored to support eyes exposed to the new normal of 8+ hours of daily screen time.
A CTRI-registered study confirmed a clinically significant 2.5× increase in Macular Pigment Optical Density, plus improved contrast sensitivity and sleep.
100% solar-powered facility certified for NSF-GMP, HACCP, ISO. KFDA approved. Available in EU Organic & NOP grades.
Backward-integrated marigold cultivation, KFDA-approved clinical proof, green ethanol extraction, and EU-ready supply.
Backward Integrated
5,000+ acres of dedicated marigold cultivation, full traceabilityRecognition No. 2025-70
Backed by a CTRI-registered clinical studyClinically Proven
Significant rise in Macular Pigment Optical Density100% Ethanol-Only
Hexane-free, food-grade, clean-label processFrom clinically proven 5:1 efficacy and KFDA approval to Rotterdam warehouse stock and complete EU documentation, MaQxan™ 204 is built for European eye-health and nutraceutical brands.
Digital screens are an inevitable part of modern life, with adults exposed to blue light for 8+ hours daily. This depletes macular pigment, affecting vision quality, contrast sensitivity and sleep.
MaQxan™ 204 restores this critical protective layer with a clinically optimised 5:1 Lutein-to-Zeaxanthin ratio — the targeted solution for Computer Vision Syndrome and screen-related macular fatigue.
Eliminate the long international shipping wait. We hold ready stock in our Rotterdam warehouse for rapid, de-risked EU distribution within 48–72 hours.
Get a QuoteMaQxan™ 204 is supplied in standardised, formulation-ready grades and forms for European eye-health, supplement and functional food applications. Recommended use: 20 mg Lutein + 4 mg Zeaxanthin (5:1) twice daily.
| Grade / Form | Standardisation | Typical Application |
|---|---|---|
| MaQxan™ 204 Powder | 5:1 Lutein : Zeaxanthin by HPLC | Capsules, tablets, premium eye-health supplements |
| Water-Dispersible Powder | 5:1 L:Z, 20% WD by HPLC | Functional beverages, gummies, sachets, RTDs |
| Oil Suspension | 5:1 L:Z, ultra-refined sunflower oil | Softgels and high-bioavailability formats |
| Beadlets / Granules | 5:1 L:Z by HPLC | Direct-compression tablets and premixes |
| Custom Grade | Available on Request | Bespoke to customer formulation requirements |
Custom specifications can be developed on request. Contact us for certificates of analysis, safety data sheets, and technical documentation.
MaQxan™ 204 is backed by a CTRI-registered clinical study and a robust pre-clinical foundation, with official KFDA approval.
CTRI/2022/12/048392 · Randomised, placebo-controlled, crossover study
The study enrolled 60 healthy individuals (aged 18–55 with 8+ hours of daily screen time) over an 8-month protocol, supplementing 20 mg Lutein + 4 mg Zeaxanthin twice daily.
Results confirmed a clinically significant 2.5× increase in MPOD (baseline 0.22 rising to 0.65 at 4 months), with significant gains in contrast sensitivity and a 58% improvement in sleep duration and quality.
Long-term use was confirmed safe, with intraocular pressure, retinal thickness and liver/renal function all remaining within normal ranges.
Request Clinical DossierMacular Pigment Optical Density (MPOD)
Placebo vs MaQxan™ 204 across study groups — higher is better
Common questions from European eye-health and nutraceutical brands about MaQxan™ 204 Lutein & Zeaxanthin.
Request a sample, bulk quote, clinical dossier or technical documentation for MaQxan™ 204 Lutein & Zeaxanthin. Our team responds within one business day.
Or write to us at: enquiry@ingexgermany.de